Real-world Evidence from a Retrospective Multicentre Analysis on First-line Therapy for Metastatic Papillary Renal Cell Carcinoma. A GUARDIANS Project.

ABSTRACT:

Background and objective

Papillary renal cell carcinoma (pRCC) is a rare disease. The optimal treatment of metastatic pRCC is still unclear. We evaluated real-world treatment outcomes of first-line treatment in this cohort in Germany.

Methods

Patients with advanced or metastatic pRCC were eligible. Adverse events (AEs) were reported according to Common Terminology Criteria for Adverse Events version 5.0. The overall response rate was accessed according to the local standard. Progression-free survival (PFS) was calculated from the start of treatment to progression or death. Descriptive statistics and Kaplan-Meier plots were utilised, where appropriate.

Key findings and limitations

In total, 121 suitable patients (77% male) with a median age of 63 yr (quartiles 55, 70)

SUBMITTER: Hilser T 

PROVIDER: S-EPMC12280342 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature